Welcome to our dedicated page for Avantor news (Ticker: AVTR), a resource for investors and traders seeking the latest updates and insights on Avantor stock.
Based in Center Valley, PA, Avantor, Inc. (NYSE: AVTR) is a global leader in providing mission-critical products and services to customers in diverse industries such as life sciences, healthcare, education and government, as well as advanced technologies and applied materials. Avantor's portfolio includes high-performance chemistries and materials marketed under reputable brand names such as J.T.Baker®, Macron Fine Chemicals™, Rankem™, BeneSphera™, and POCH™. The company's offerings span materials and consumables, equipment and instrumentation, as well as services and specialty procurement.
Operating across three geographical segments—Americas, Europe, and AMEA—Avantor generates a majority of its revenue from the Americas. Recent strategic initiatives include a partnership with Tobin Scientific to support end-to-end biopharma logistics, enhancing Avantor's ability to provide cold chain and ambient storage solutions for lab relocations and sample transport. This collaboration ensures current Good Manufacturing Practice (cGMP) compliance and aims to streamline complex logistics, thereby allowing customers to focus on advancing their research.
In addition to its commitment to operational excellence, Avantor is making strides in sustainability. The company recently introduced an innovative packaging system that optimizes product-to-package ratios, significantly reducing shipping material usage. This system has already saved thousands of pounds of filler material, exemplifying Avantor's dedication to eco-friendly practices.
Financially, Avantor reported net sales of $1.72 billion for Q3 2023, a 7.3% decline compared to the previous year, largely due to organic sales dips and COVID-19 headwinds. Despite these challenges, Avantor achieved more than 110% free cash flow conversion, facilitating ongoing debt reduction. The company also reaffirmed its FY2023 guidance, underscoring its confidence in long-term growth prospects by implementing a new operating model and advancing a $300 million cost optimization initiative.
Avantor’s global footprint gives it access to over 300,000 customer locations in 180+ countries, thereby positioning it as a crucial partner in facilitating scientific breakthroughs and innovation. For more information, visit avantorsciences.com.
Avantor, Inc. (NYSE: AVTR) announced a definitive agreement to acquire Masterflex bioprocessing business from Antylia Scientific for $2.9 billion, netting $2.7 billion after tax benefits. Masterflex, based in Illinois, focuses on peristaltic pumps and single-use fluid transfer technologies, generating approximately $300 million in estimated 2022 revenues. This acquisition aims to enhance Avantor's biopharma offerings, contributing to revenue growth and margin improvement. Completion is expected in Q4 2021, subject to regulatory approvals.
Avantor, Inc. (NYSE: AVTR) announced a multi-year investment to enhance its global hydration capabilities, completing a significant facility expansion in Gliwice, Poland, and initiating further expansion in Aurora, Ohio, projected to finish by mid-2022. This investment aims to support the biopharmaceutical industry's increasing demand for biologics by outsourcing buffer preparation, which can streamline workflows and accelerate therapy production. The expanded facilities will improve Avantor's ability to offer WFI-quality water buffer manufacturing, enhancing support for biopharma manufacturers globally.
Avantor, a global leader in mission-critical products for various industries, announced a virtual investor day scheduled for September 9, 2021, at 9:00 a.m. EDT. The event will be accessible via webcast on their official website, where a replay will also be available post-event. Avantor serves over 225,000 customer locations globally, impacting research and production across biopharma, healthcare, education, and advanced technology sectors. The company emphasizes forward-looking statements, cautioning that these may involve risks and uncertainties.
Avantor, Inc. (NYSE: AVTR) reported robust financial results for Q2 2021, with net sales of $1.86 billion, up 25.7% year-on-year. Net income surged 162.1% to $157.8 million. The company achieved 34.2% growth in Adjusted EBITDA to $366.6 million, with a margin expansion of 125 basis points. Despite two acquisitions, Ritter GMBH and RIM Bio, having no significant impact on quarterly results, the company raised its full-year guidance, reflecting confidence in ongoing momentum across various markets.
Avantor (NYSE: AVTR) announced a quarterly cash dividend of $0.78 per share for its 6.250% Series A Mandatory Convertible Preferred Stock, translating to a rate of 1.560%. This dividend is payable on August 16, 2021 to shareholders of record as of August 1, 2021. As a leading global provider of essential products and services across life sciences and technology sectors, Avantor's substantial footprint serves over 225,000 customer locations in more than 180 countries, underscoring its influence in critical research and development activities.
Avantor, Inc. (NYSE: AVTR) has announced a change in the schedule for its second quarter 2021 earnings release. The financial results will now be disclosed after market close on July 29, 2021, followed by a conference call on July 30, 2021, at 7:30 a.m. EDT. Interested participants can join the call by dialing (866) 211-4132 domestically or (647) 689-6615 internationally. A live webcast will be available on the company’s investor webpage, with a replay accessible until August 28, 2021.
Avantor, Inc. (NYSE: AVTR), a global provider of essential products and services, will release its Q2 2021 financial results after market close on July 28, 2021. The company will host a conference call at 5:00 p.m. EDT to discuss these results. Interested participants can join via phone or through a live webcast on Avantor's investor website. The earnings press release and presentation will also be available. Avantor serves over 225,000 customer locations worldwide, emphasizing its significant role in the life sciences and advanced technologies sectors.
Avantor, Inc. (NYSE: AVTR) has successfully completed the acquisition of Ritter GmbH, enhancing its capabilities in clinical diagnostics and life sciences research. This strategic move integrates Ritter's liquid dispensing technology with Avantor's lab automation solutions, aiming to deliver greater value to biopharma and healthcare customers. Ritter, known for high-quality robotic and liquid handling consumables, specializes in various diagnostic applications, further bolstering Avantor's extensive portfolio. The acquisition received all necessary regulatory approvals.
Avantor (NYSE: AVTR) announced on June 1, 2021, the acquisition of RIM Bio, a prominent Chinese producer of single-use bioprocess bags for biopharmaceutical manufacturing. This strategic purchase enhances Avantor's capacity in the AMEA region, establishing its first single-use production plant there. The acquisition aims to leverage RIM Bio's proprietary technologies, thereby expanding Avantor's offerings in bioproduction and addressing increasing global demand in the biopharma sector. The move aligns with Avantor's ongoing investments in China.
FAQ
What is the current stock price of Avantor (AVTR)?
What is the market cap of Avantor (AVTR)?
What products and services does Avantor provide?
What are Avantor's key brand names?
What geographical regions does Avantor operate in?
How is Avantor contributing to sustainability?
What are Avantor's recent financial highlights?
What is Avantor's new operational strategy?
Who are Avantor's strategic partners?
How does Avantor support scientific research?
Where can I find more information about Avantor?
What are Avantor's plans for future growth?
